One could argue that Millennium Management's greatest advantage over other hedge funds is its ability to keep talented people in-house.
Keep Reading →
October 19 - Hedge Funds, Insider Trading
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act...
Keep Reading →
December 20 - Hedge Funds
Despite of all the negative sentiment looming around them, hedge funds had a pretty solid run for much of this year, generating positive returns for seven or eight consecutive...
Keep Reading →
November 15 - Hedge Funds, News
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience in wealth management...
Keep Reading →
June 3 - Hedge Fund Analysis, Hedge Funds, News
The deadline for the current round of 13F filings, for the quarterly period that ended December 31, is February 15.
Keep Reading →
January 12 - Hedge Funds, News
Correction: This article has previously mistakenly stated that the Redmile Group had sold shares of Array Biopharma.
Keep Reading →
September 11 - Hedge Funds, News
Jeremy Green, the manager of Redmile Group, is still bullish on Array Biopharma Inc (NASDAQ:ARRY) having further increased his holding of the stock.
Keep Reading →
August 26 - Hedge Funds, News
Jeremy Green’s Redmile Group has just acquired more shares of Array BioPharma Inc. (NASDAQ:ARRY). In a Form 4 filed with the U.S.
Keep Reading →
August 14 - Hedge Funds, News
Jeremy Green’s Redmile Group entered several new positions last quarter, as revealed by the 13F Form it filed with the U.S. Securities and Exchange Commission in February.
Keep Reading →
March 2 - Hedge Funds, News
eHealth, Inc.
Keep Reading →
January 22 - Hedge Funds, News
Jeremy Green's Redmile Group has also reduced its stake in Amicus Therapeutics, Inc.
Keep Reading →
October 9 - Hedge Funds, News
William Leland Edwards’ Palo Alto Investors disclosed today a 50% decrease in its exposure to Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Keep Reading →
October 8 - Hedge Funds, News
Not only company officers qualify as insiders.
Keep Reading →
September 16 - Hedge Funds, Insider Trading, News
Adage Capital Partners, a hedge fund led by Phill Gross and Robert Atchinson, has recently disclosed upping its stake in HeartWare International Inc (NASDAQ:HTWR).
Keep Reading →
September 12 - Hedge Funds, News
Perceptive Advisors, managed by Joseph Edelman, is bullish on Amicus Therapeutics Inc. (NASDAQ:FOLD). In a new filing with the U.S.
Keep Reading →
July 2 - Hedge Funds, News
James H. Litinsky's JHL Capital Group has boosted its stake in Ophthotech Corp (NASDAQ:OPHT) to 1.78 million shares, a new filing with the SEC showed.
Keep Reading →
April 15 - Hedge Funds, News
Phill Gross And Robert Atchinson's Adage Capital Management has raised its exposure to Heartware International, Inc.
Keep Reading →
December 28 - Hedge Funds, News
Jeremy Green's Redmile Group has significantly surged its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD), a new filing with the SEC revealed.
Keep Reading →
November 29 - Hedge Funds, News
Jeremy Green, Redmile Group: In a passive 13G filing with the SEC just now, the San Francisco-based Redmile Group, managed by Jeremy Green, has closed out its position in Cyclacel...
Keep Reading →
October 3 - Hedge Funds, News
To the average investor, there are a multitude of gauges shareholders can use to monitor publicly traded companies.
Keep Reading →
September 17 - News
Now, according to many investors, hedge funds are assumed to be overrated, outdated investment tools of an era lost to time.
Keep Reading →
September 17 - News
To the average investor, there are tons of metrics shareholders can use to analyze Mr. Market. A duo of the best are hedge fund and insider trading interest.
Keep Reading →
September 15 - News
To the average investor, there are tons of methods market participants can use to track publicly traded companies.
Keep Reading →
September 13 - News
To many of your peers, hedge funds are assumed to be delayed, outdated financial tools of a period lost to current times.
Keep Reading →
September 13 - News
At the moment, there are dozens of gauges investors can use to track Mr. Market. A pair of the most under-the-radar are hedge fund and insider trading movement.
Keep Reading →
September 6 - News
In the 21st century investor’s toolkit, there are tons of gauges investors can use to track the equity markets.
Keep Reading →
September 5 - News
To the average investor, there are dozens of methods investors can use to track publicly traded companies. Two of the best are hedge fund and insider trading sentiment.
Keep Reading →
September 4 - News
To many of your peers, hedge funds are viewed as delayed, old investment tools of an era lost to time.
Keep Reading →
September 4 - News
In today’s marketplace, there are dozens of methods market participants can use to watch the equity markets.
Keep Reading →
September 3 - News
To the average investor, there are many gauges shareholders can use to analyze the equity markets. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
September 2 - News
In the financial world, there are a multitude of metrics shareholders can use to watch their holdings.
Keep Reading →
August 30 - News
At the moment, there are many methods investors can use to analyze Mr. Market. Some of the most innovative are hedge fund and insider trading sentiment.
Keep Reading →
August 30 - News
To many of your fellow readers, hedge funds are viewed as delayed, outdated investment tools of a forgotten age.
Keep Reading →
August 28 - News
If you were to ask many of your peers, hedge funds are viewed as overrated, outdated financial tools of an era lost to time.
Keep Reading →
August 26 - News
In today’s marketplace, there are a multitude of indicators market participants can use to watch stocks.
Keep Reading →
June 24 - News
In the eyes of most traders, hedge funds are seen as slow, old financial vehicles of years past.
Keep Reading →
June 19 - News
Insulet Corporation (NASDAQ:PODD) was in 14 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 14 - News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds' portfolio at the end of March.
Keep Reading →
June 14 - News
